Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis.

Autor:	Alva N; Facultad de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.; Unidad de Revisiones Sistemáticas y Meta-Análisis, Tau-Relaped Group, Lima, Peru., Martínez AR; Facultad de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.; Unidad de Revisiones Sistemáticas y Meta-Análisis, Tau-Relaped Group, Lima, Peru., Ortiz-Saavedra B; Facultad de Medicina, Universidad Nacional de San Agustín de Arequipa, Arequipa, Peru., Montes-Madariaga ES; Unidad de Revisiones Sistemáticas y Meta-Análisis, Tau-Relaped Group, Lima, Peru.; Facultad de Medicina, Universidad Nacional de San Agustín de Arequipa, Arequipa, Peru., Cotrina A; Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru., Caballero-Alvarado JA; Facultad de Medicina, Universidad Privada Antenor Orrego, Trujillo, Peru., Sah R; Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.; Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, India.; Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, India., Barboza JJ; Escuela de Medicina, Universidad Cesar Vallejo, Trujillo, Peru.
Jazyk:	angličtina
Zdroj:	Frontiers in pediatrics [Front Pediatr] 2023 Aug 04; Vol. 11, pp. 1202927. Date of Electronic Publication: 2023 Aug 04 (Print Publication: 2023).
DOI:	10.3389/fped.2023.1202927
Abstrakt:	Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and laser therapy. Material and Methods: Electronic searches will be carried out in medical databases with key words and controlled vocabulary terms. Randomized controlled trials (RCT) will be assessed. The primary outcome will be the full ROP regression. Two reviewers will extract the data using predefined forms and, to assess the quality of the study, we will use RoB 2.0, the tool for randomized controlled trials developed by the Cochrane Collaboration. We used a combination of the inverse-variance approach and random-effects models for the meta-analysis. Results: The eyes of 182 preterm infants who had ranibizumab treatment were assessed in a total of 364 eyes, and 135 infants received laser therapy. The follow-up period was between 6 and 24 months. Ranibizumab was not associated with greater regression of ROP compared to laser therapy in preterm infants (RR: 1.09, CI 95%: 0.95-1.24; p : 0.22). Also, ranibizumab was not associated with recurrence of ROP compared to laser therapy in preterm infants (RR: 3.77, CI 95%: 0.55-25.81; p : 0.22). Conclusions: The efficacy of ranibizumab compared to laser is very uncertain in terms of ROP regression and decreased ROP recurrence in preterm infants. Systematic Review Registration: identifier PROSPERO (CRD42022324150). Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2023 Alva, Martínez, Ortiz-Saavedra, Montes-Madariaga, Cotrina, Caballero-Alvarado, Sah and Barboza.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu